Living kidney donation continues as the cornerstone of transplantation. In order to determine with ever-renewing assurance that living donation is safe for the donor, we need to periodically review the literature, review the United Network for Organ Sharing database for donor characteristics that may put them in danger, and scour databases for donors starting dialysis and/or listed for transplant. Additionally, we must encourage financing studies that follow large diverse cohorts of donors over their entire lifetimes in order to detect key characteristics that influence outcomes. Currently, it can be stated that living donation is, on the whole, safe, with few perioperative deaths, complications, or long-term medical issues. Additionally, the living donor reflects the demographics of the general population including increased rates of obesity with some donors having hypertension and low-grade proteinuria. In the long run, death rates (for the white donor) are no different than for the general population, whereas end-stage renal disease rates are slightly increased over the general population, ranging from 0.1% to 1.1%. The higher risk is especially notable in the black donor. Preeclampsia in female donors may also be marginally greater than in those with 2 kidneys. Thus, the new health age brings a rejuvenated responsibility of the medical community and those in governance to design systems that allow more complete and continued follow-up of the living kidney donor, especially those of color.
L iving kidney donation is at center stage in the treatment paradigm for patients with end-stage renal disease (ESRD) (Fig 1) . Also, attracting the spotlight is the concern over the long-term consequences of living donation even though they are extensively evaluated and highly selected to be healthy at the time of donation. This article reviews what is known to date about the hard outcomes of death, postoperative complications, and ESRD in living donors. In addition, donors' current demographics and physical condition will be described, after which several policy issues are discussed. The anticipated changes in donor risk must be placed into context with the donor's willingness to provide benefit to their recipient. Furthermore, we need to assess the donor in the context of our changing society and changing risks for developing chronic disease, while continuing to investigate their risk of adverse outcomes in the setting of contemporary medical realities such as obesity, diabetes, and a lack of access to health care.
Short-Term Risks of Living Kidney Donation

Donor Mortality
Death after living donation is quite rare, with the risk of death reported as 0.02% to 0.04% within 90 days of donation. [1] [2] [3] From the initiation of the United Network for Organ Sharing (UNOS) tracking of donor deaths in October 1999 through December 2007, 14 living kidney donor deaths (out of 51,153 donors, 0.03%) that occurred within 30 days of donation were reported to UNOS or identified by examination of the Social Security Death Master File. The most common reasons for death at any time (range ¼ 0-2688 days) (N ¼ 154 for the cohort, plus 1 donor whose cause of death is recorded as predonation coma) are listed in Table 1 . Even though donors reportedly undergo a thorough evaluation before donation, some causes of death (eg, myocardial infarction, cancer, suicide, and homicide) within a short time after donation point to a need for programs to review their donor outcomes in the context of their program's predonation medical and psychosocial evaluations. Even within a highly selected population, complications will occur, and the question remains as to whether even more of such complications are preventable?
Short-term Living Donor Risks
Short-term Postoperative Complications
Acute postoperative complications reported by programs to UNOS generally include bleeding, gastrointestinal injury and/or malfunction, venous thromboembolism, and reoperation. 2 Analyses of short-term (6 weeks after donation) outcomes for living kidney donors in the OPTN/UNOS data have found that 3.9% of the living kidney donors who donated in 2005 and 2006 (N ¼ 13,006), had at least 1 adverse event. The most common events including reoperation are enumerated in Table 2 . The most common reasons for reoperation were bleeding (n ¼ 25), bowel obstruction (n ¼ 8), and hernia repair (n ¼ 7). The most common reason for donor readmission was an abdominal problem (n ¼ 105; eg, nausea, vomiting, gastroenteritis, abdominal pain, ileus, constipation, or bowel obstruction). Less frequent reasons included chylous ascites, pancreatitis, shortness of breath, pulmonary embolism, subphrenic fluid, and infection (eg, wound, pneumonia, or urinary tract). Because over 50% of Living Donor Registration forms were submitted by transplant centers less than 6 weeks after donation, these data are all considered minimum estimates. Higher complications rates have been reported when donors themselves are the reporter. 4 
Short-term Kidney Outcomes
By inulin clearance determinations of the glomerular filtration rate (GFR) and para-aminohippuric acid determinations of effective renal plasma flow, we know that the average decrease in overall GFR after donation is 20% Living Kidney Donors to 30% (69/104) and for renal plasma flow it is 30% to 40% (349/536). 5 This is at the expense of hyperfiltration in the remaining kidney. 6 The absolute ability to increase GFR is dependent on age and obesity. Obese young donors do not retain the ability to fully compensate for the loss or renal, and, although older donors do increase single kidney GFR, the absolute increase is comparatively less. 5 
Living Donor Issues
Pregnancy After Living Donation
Many young women consider living donation before completing their childbearing. The classical teaching from a prior survey was that pregnancy was not negatively impacted by a previous unilateral nephrectomy. 7 However, researchers in Norway who linked data from birth records and the living donor registry discovered that women who donated (N ¼ 306 donors: 726 pregnancies, with 106 pregnancies after donation) had a higher rate of preeclampsia after donation (5.7%) in comparison to the rate before donation (2.6%) and that of randomly chosen Norwegian birth registry controls (3.5%) at a ratio of 1,000:1. 8 The differences were significant when comparing pre-versus postdonation pregnancies; when adjusted for maternal age and parity, the P value was ,.001. There was also an insignificant increase in gestational hypertension after donation (1.8% of donors predonation, 2.8% of donors postdonation, 1.4% of controls). 8 These findings are supported by a survey of female donors from the University of Minnesota who had pre-and/or post-donation pregnancies (n ¼ 822 donors with 2,426 pregnancies before donation; n ¼ 223 donors with 459 pregnancies after donation). In this survey, predonation preeclampsia was reported in 0.7% of pregnancies and postdonation in 5.2% (P , .0001), whereas gestational hypertension was noted in 0.4% predonation and in 4.4% (P , .0001) after donation. 8 Additionally, gestational diabetes was reported in 0.7% before donation and 2.4% (P ¼ .0004) after. Although this new information must be recognized for what it is, self-reported survey data without fixed criteria for the diagnosis of preeclampsia or hypertension, it provides an impetus for further investigation. An additional note of caution is due. These data are only valid in the white population because women of other racial and ethnic backgrounds were not included in either study.
Long-term Studies of Living Donor Survival
Long-term outcomes reported from singlecenter studies in largely white populations have revealed outcomes equal to or better than the general population. [9] [10] [11] [12] [13] [14] The newest information on long-term outcomes is again from 2 studies of whites, one from Minnesota and one from Toronto. 15 Renal functional studies revealed that 85.5% of donors, at a mean of 12.9 6 9.2 years after donation, had a GFR $60 mL/min/1.73 m 2 . Hypertension was noted in 32.15% and albuminuria in 12.7%. Older age and higher body mass index were associated with a GFR ,60 mL/min/1.73 m 2 and hypertension. A longer time period from the time of donation was associated with albuminuria. Most donors had quality of life scores greater than population norms. Notably, limitations of the study include an ethnically uniform population, the lack of a comparably medically evaluated control population, and the evaluation of only a proportion of the donor population. Even mild degrees of kidney insufficiency and albuminuria have been associated with increased risks for cardiovascular disease. 17 Given this association, concern for increased cardiovascular risk in living donors has been raised. However, Garg et al 16 16 They did, however, report a significant increase in the number of living donors with hypertension (16.3%) compared with the control group (11.9%; hazard ratio ¼ 1.4, confidence interval, 1.2-1.7). This is concordant with the data from a previous meta-analysis of long-term donor outcomes where by 10 years there was an average 5-mm Hg increase in donor blood pressure compared with age-and sex-matched controls. 18 In addition to classically ''normal'' donors who have been highly medically selected, it has recently been published that individuals with medical abnormalities are donating.
19-22
The long-term risks to these donors are not yet well delineated. Medical issues in need of more study in the setting of kidney donation include but are not limited to renal artery stenosis, hypertension, morbid obesity, mild glucose intolerance, nephrolithiasis, and thin glomerular basement membranes. [22] [23] [24] [25] [26] 
ESRD in Living Donors
Recent research has found that between 0.1% and 1.1% of living donors have developed ESRD. 15, [27] [28] [29] [30] [31] Follow-up of the 3,698 living donors from the University of Minnesota has revealed that 11 (0.29%) developed ESRD 22.5 6 10.4 years after donation; 7 of the donors were women, and 8 were white. 15 This roughly described an estimated incidence of ESRD in donors of 180 per million persons per year as compared with the overall adjusted incidence rate of 268 per million persons per year in the white population of the United States. More current analyses of the OPTN data by Cherikh et al 32 revealed that 148 previous living kidney donors were on the kidney waiting list between January 1, 1996, and March 31, 2007. Most of the donors who were later listed for a kidney had donated between the ages of 18 and 34 and to a full sibling. Of special concern was their finding that the median time from donation to listing was 21 years for white donors and 16 years for black donors, implying that short-term follow-up of living donors may not adequately capture or quantify this risk. Also of worry was the finding that 43% of such donors were blacks who comprised and continue to compromise nearly 12% of living kidney donors. These data suggest that risks of postdonation ESRD are unequal among various ethnic/racial groups and mirror the increased risk of ERSD that these higher-risk groups experience within the general population.
32-34
The most frequent reported causes of ESRD in living kidney donors after those categorized as ''unknown'' are glomerular diseases (primarily focal and segmental glomerulosclerosis), hypertensive nephrosclerosis, diabetes, and renovascular/other vascular diseases. 1, 32 One recent study of black donors who had been recruited to return for evaluation after donation (between March 1996 and February 2002) at the University of Maryland disclosed that of the 39 of 107 black donors who returned, 41% had hypertension. Notably, it was unknown to the donor in 20.5% of cases. 35 Furthermore 2.6% had diabetes. Microalbuminura was noted in 15.4% and macroalbuminuria in 2.6%. Chronic kidney disease was present in 17.9% using the Modification of Diet in Renal Disease Study 4 equation for staging. However, although it is known that estimated GFR equations do not perform well in living donor populations before or after donation, 36, 37 hypertension and other metabolic syndrome characteristics may be an explanation for the increased risk for ESRD in African American donors. Furthermore, the risk for focal and segmental glomerulosclerosis and hypertensive renal disease in blacks has recently been genetically linked to variations of the nonmuscle myosin heavy chain 9, which may foster alterations in intrarenal hemodynamics that are more Living Kidney Donors pathophysiologically problematic in certain AA donors. 5, [38] [39] [40] [41] Future investigations in living AA donors should include testing for such genotypic variation. Lastly, it should be noted that the data on donor ESRD do not include those who started dialysis but were not listed for transplant or those who died with ESRD but did not receive renal replacement therapy. A report of this analysis has finally been performed and is forthcoming.
Current Demographics of Living Donors in the United States
Relationships
The relationship between living donors and their recipients has changed over time. Today, donors are less likely to be blood relatives (eg, parents and siblings) of the recipient and instead are spouses and friends. Another trend is the increased donation by adult offspring to their parents, increasing from 9% of living kidney donors in 1989 to 18.7% in 2006.
1 An additional shift in donor demographics is the increase in donation by unrelated and emotionally uninvolved donors (altruistic or nondirected donors). Although altruistic donor numbers are increasing, these constitute only a small proportion of all living donors (N ¼ 68, 1.1% in 2006).
A hybrid of sorts between traditional directed donation and altruistic donation is a relatively new phenomenon known as kidneypaired donation: 2 prospective recipients each have a willing living donor with whom they are not compatible (Fig 2) . These donations occur in the setting of original donor recipient ABO incompatibility or positive crossmatch.
Age
Donor age is increasing in concert with recipient age (Table 3) . 20, [42] [43] [44] Specifically some recipients are age 80 years or older. In 1995, 5 living donor recipients were between the ages of 75 and 79; no recipient of a living donor was over the age of 80 years. In the year 2000, there were 3 recipients of living donor kidneys who were age 80 years or older. From that time onward, annually, about 50 living kidney recipients were at age 75 to 9 years and 6 were age 80 years or older.
Medical Characteristics
The complex medical donor as determined by the UNOS database was reviewed by Reese et al. 19 They reported that 24% of donors in 2004 to 2005 were medically complex, with medical complexity defined as the presence of hypertension, obesity, or an estimated GFR,60 mL/min/1.73 m 2 . The acceptance of complex donors was driven by center living donor activity and not by market forces. Changes over time in the acceptance of medically complex donors can also be shown from the UNOS database. The numbers of living donors over age 50 has increased 3-fold since 1995. Obesity is on the rise and was present in 17% of donors in 2000. It is now increasing its presence to 21% in 2007.
Studies of Kidney Biopsies in Living Donors
Preimplantation biopsies representing donor kidney histology have been performed at the time of transplantation in several studies. [45] [46] [47] One of the largest and most impressive studies was by Mancilla et al, 47 an analysis of 231 patients, with 219 adequate donor biopsies taken at the time of donation. The average age of the donors was 35 6 10 years, with an average blood pressure of 115 6 9 mm Hg/73 6 7 mm Hg. Of the adequate biopsies, 100 were absolutely normal; however, the remainder had abnormal findings. Interstitial fibrosis was seen in 64 of the 119, tubular atrophy in 29, mesangial expansion in 26, arteriolar hyalinosis in 23, and glomerulosclerosis in 23. Associations of these findings with age, serum creatinine, blood pressure, and body mass index were found. More detailed evaluation of donor outcomes, according to renal histology at donation, is required, preferably with quantification of the degree of nephrosclerosis, global sclerosis, and interstitial fibrosis. Likewise, genetic and proteomic studies will be helpful in evaluating the processes that lead to renal function loss.
Insurance Coverage
Analysis of the 2003 National Inpatient Sample, a nationally representative 20% sample of US hospital stays revealed that 16.9% of incident organ donors, identified by using International Classification of Diseases, 9th Edition, Clinical Modification diagnosis and procedure codes, were uninsured. 48 This compared with 0.8% of transplant recipients. In a multivariate analysis of comparison to other inpatients, organ donors were much more likely to be uninsured. This is comparable to information from the UNOS database, which is currently undergoing further analysis. The UNOS database also delineates some variability in insurance coverage by race of the donor. Importantly, the recipient's insurance realistically only covers complications related to donation in a time-limited fashion. Nationally, no policy addresses the length of time that complications, arising from donation, are covered or the responsible insurance plan.
Selection of Living Donors
Criteria used to select living donors have changed over time. Mandelbrot et al 20 investigated the change between 1995 and 2006 in transplant center selection practices. The most significant changes were the acceptance of living unrelated donors and the elimination of an upper age for donation. Additionally, programs were more likely to accept donors with hypertension and a history of kidney stones provided certain additional criteria were met. Today, programs are less likely to accept as donors those who are younger, moderately obese, and have a lower creatinine clearance. Even so, considerable variability remains among transplant programs in the testing methods and criteria used for donor selection.
Living Donation and Medical Policy
The process surrounding living donation is evolving. Recently, several conferences have been held to discuss the consent for, evaluation of, and care of living donors. [49] [50] [51] Additionally, UNOS has produced resource documents to help programs benchmark their consent and evaluation processes. Internationally, countries have banded together to discourage and, in fact, eradicate paid donation. This is on the heels of information from Pakistan, Iran, and the Philippines regarding the negative impact of cash payment to donors on their health and the health of their recipients. [52] [53] [54] [55] Even so, this debate continues on with different versions of remuneration under discussion in many parts of the world. Nevertheless, the sense of long-term commitment to the living donor is growing. Ethically, most 
Conclusion
Concurrent with increased living kidney donation has been the recognition of the complex donor. 19 Approximately, 24% of current living kidney donors have some medical abnormality. In our present medical environment, approximately 17% of living donors are without health insurance. Given the low but real risk of medical problems after living donation and in particular ESRD, it is important for us to strongly consider those means that provide medical follow-up to all living donors. We are compelled to keep track of our donors, anticipate and interdict problems where feasible, and use this information to educate future, prospective donors. Categorizing medical follow-up and care of possible complications of donation as valued consideration is nonsensical. How can the active encouragement of persons to put themselves in harm's way, without a safety net, ever be considered ethical? Moreover, how can providing the safety net for conditions potentially and directly linked to donation be considered in the same category as cash payment for organs? Without a program that definitively delineates complications and medical care of donors, the United States cannot enjoin those countries that support the Declaration of Istanbul, which recently established our international standards for donor care and safety. 51 
